Novel S-Nitrosoglutathione Reductase Inhibitors

A method of treatment of a disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof

• wherein
• X is selected from the group consisting of O and S;
• Y is selected from the group consisting of O and S;
• Z is selected from the group consisting of Z1, Z2, Z3, and Z4, wherein
• Z1 is
• Z2 is
• Z3 is
• and
• Z4 is
• provided that Z is only Z4 when at least one of X or Y is S;
• R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)haloalkyl, unsubstituted aryl(C1-C4)alkyl, substituted aryl(C1-C6)alkyl, (C1-C6)heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
• R2 is selected from the group consisting of hydrogen, halogen, cyano, and (C1-C6) alkoxy;
• R3 is selected from the group consisting of hydrogen, halogen, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, cyano, and N,N-dimethylamino;
• R4 is selected from the group consisting of tetrazole, oxadiazolone, thiadiazolone, methylsulfonylcarbamoyl, and N-hydroxycarbamoyl;
• and
• R5 is selected from the group consisting of carboxy, tetrazole, oxadiazolone, thiadiazolone, methylsulfonylcarbamoyl, and N-hydroxycarbamoyl.